← Oncology Approval Tracker

FDA DECISION ·

Libtayo + platinum-based chemotherapy

cemiplimab-rwlc plus platinum-based chemotherapy · Regeneron

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line therapy with platinum-based chemotherapy for adults with locally advanced NSCLC unsuitable for resection or definitive chemoradiation, or metastatic NSCLC, without EGFR, ALK or ROS1 aberrations.

LAMPGEN ANALYSIS

Why it matters

The action extends cemiplimab use to a first-line combination with a platinum regimen.

What research teams should watch

Document molecular testing, stage and reasons for ineligibility for definitive local treatment when applicable.

PRIMARY RECORDS

Sources